Compass Therapeutics · pitchdeck
Compass Therapeutics | Investor Presentation Deck | 40 slides
40 pages · 0 arc beats · 3 loops
Compass Therapeutics | Investor Presentation Deck | 40 slides
Compass Therapeutics · 2023-05 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
1246810121416182022242628303234363840
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 40 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 40 slides 100% 40/40 slides 100% 40/40 slides · 180 hits — 0/40 slides
35% 14/40 slides 27.5% 11/40 slides — 0/40 slides
27.5% 11/40 slides Slide inventory
40 every slide · same image gating as the playbook
03
The slide uses a ribbon-style list format to categorize key company pillars.summarize
04
The chart uses a Gantt-style visualization to represent clinical trial progress across different indications.plan_implementation
05
The slide uses a two-tier organizational structure (Senior Executive Team vs Vice Presidents) and includes a footer for the Chairman of the Board.other
06
The slide features a large compass-like icon, suggesting a focus on direction or a specific target.transition
07
The slide illustrates the mechanism of action of CTX-009 as a bispecific antibody and compares the effects of single-agent anti-VEGF vs anti-DLL4 blockade.present_solution
10
The chart displays individual patient responses categorized by cancer type (Gastric, CRC, Other) and dosage (mpk).show_traction
Open slide detailLoop · Hypothesis Test
11
The table highlights Partial Response rates with a red border.analyze_data
Open slide detailLoop · Hypothesis Test
12
The chart uses a standard waterfall plot to visualize clinical efficacy (tumor shrinkage).show_traction
Open slide detailLoop · Hypothesis Test
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.analyze_data
Open slide detailLoop · Hypothesis Test
15
The slide illustrates a standard Simon 2-stage design, a common statistical framework for phase II oncology trials.present_framework
16
The table highlights patient age, gender, ECOG status, prior therapies, and BTC subtypes.analyze_data
17
The chart is a classic waterfall plot used in oncology to demonstrate drug efficacy.show_traction
19
The slide presents key clinical efficacy endpoints for a Phase 2 study.show_traction
21
The slide compares clinical trial data for a specific drug combination against known safety profiles of standard-of-care components.compare_peers
22
The table compares a mixed 2L/3L cohort (CTX-009) against historical 1L and 2L benchmarks.compare_peers
Open slide detailLoop · Confession
23
The slide compares internal trial data for CTX-009 against historical benchmarks (FOLFOX and TOPAZ-1) to demonstrate efficacy.compare_peers
Open slide detailLoop · Confession
24
The slide outlines a randomized clinical trial structure with two arms (CTX-009 + Paclitaxel vs Paclitaxel alone) and a crossover provision.plan_implementation
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.size_opportunity
Open slide detailLoop · Cost Of Inaction
26
The slide outlines a standard Simon 2-stage design where recruitment stops if the objective response rate (ORR) threshold is not met in the first stage.plan_implementation
Open slide detailLoop · Cost Of Inaction
27
The slide uses a table for epidemiological data and a horizontal layout to represent the treatment pathway.size_opportunity
Open slide detailLoop · Cost Of Inaction
28
The slide uses a simple sequential block layout to represent a development roadmap.plan_implementation
30
The slide highlights clinical efficacy in Phase 1a and 1b trials for various cancers.present_solution
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.illustrate_case
34
Shows a process flow from initial synergistic discovery to the final optimized bispecific molecule (CTX-8371) and its validation data.show_traction
35
The slide uses a visual comparison framework to contrast standard PD-1 blockers with the proprietary CTX-8371 mechanism.present_solution
36
The slide shows tumor volume over time, tumor growth inhibition percentages, individual tumor growth trajectories, and a summary table of cure rates.show_traction
40
The timeline uses color-coded dots (blue vs red) to distinguish between different drug programs or milestone types.plan_implementation